Hypoxia　and　high　glutathione　(GSH)　contents　in　the　tumor　microenvironment　(TME)　diminish　the　efficacy　of　single-modality　photodynamic　therapy　(PDT)　and　chemodynamic　therapy　(CDT).　Cu2O　can　effectively　release　Cu+　within　the　TME,　facilitating　CDT,　and　concurrently　generate　O2　to　mitigate　hypoxia.　Co-delivery　of　Cu2O　with　photosensitizers　(PSs)　to　tumors　could　potentially　enhance　PDT/CDT　combination　therapy.　However,　challenges　such　as　instability,　susceptibility　to　in　vivo　substances　affecting　catalytic　activity,　and　toxicity　to　normal　tissues　limit　the　utility　of　Cu2O.　To　overcome　these　limitations,　we　propose　the　utilization　of　Cu2O　as　the　core　within　GSH-responsive　metal-organic　framework　(MOF)　shells,　uniformly　grown　on　its　surface　to　form　Cu2O@MOFs　heterostructures.　This　design　effectively　prevents　leakage　and　deactivation　of　the　Cu2O　core.　We　synthesized　Cu2+-doped　ZIF-67　multifunctional　MOF　shells　in　situ　on　Cu2O　and　subsequently　incorporated　the　photosensitizer　ZnPc　into　the　MOFs　to　create　Cu2O@Cu2+/ZIF-67@ZnPc　(CCZZ).　Upon　entry　into　tumor　cells,　this　nanodrug　degrades　in　the　presence　of　slight　acidity　and　an　optimal　GSH　concentration,　releasing　Cu2O　and　ZnPc　while　depleting　GSH.　The　released　Cu2O　and　degraded　ZIF-67,　respectively,　generate　Cu+　and　Co2+　for　CDT　and　O2,　while　the　ZnPc　consumes　O2　for　PDT　under　laser　irradiation,　achieving　synergistic　PDT/CDT　combination　therapy.　To　the　best　of　our　knowledge,　this　is　the　first　study　based　on　the　in　situ　synthesis　of　Cu2O@Cu-MOFs　that　achieves　dual-enhanced　PDT/CDT　therapy　by　simultaneously　depleting　GSH　and　generating　oxygen.